Drug Insight: Insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - A reappraisal

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 5, 2008, Pages 272-283

  Dunaif, Andrea ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Infertility; Insulin resistance; Metformin; Polycystic ovary syndrome; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CLOMIFENE CITRATE; DEXTRO CHIRO INOSITOL; DIANE; ETHINYLESTRADIOL; GESTAGEN; INOSITOL DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; SULFONYLUREA; TROGLITAZONE; UNCLASSIFIED DRUG;

ANEMIA; ANOVULATION; BODY COMPOSITION; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIVE BIRTH; LIVER TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PERIPHERAL EDEMA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SPONTANEOUS ABORTION; STOMACH PAIN; VOMITING; WEIGHT GAIN;

EID: 42449144300     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0787     Document Type: Review

References (102)

1. Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333: 853-861
2. Knochenhauer ES et al. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078-3082
3. Diamanti-Kandarakis E et al. (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006-4011
4. Stein I and Leventhal M (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29: 181-191
5. Goldzieher JW and Green JA (1962) The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 22: 325-338
6. Burghen GA et al. (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50: 113-116
7. Sam S and Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14: 365-370
8. Apridonidze T et al. (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929-1935
9. Grundy SM (2002) Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105: 2696-2698
10. Solomon CG (1999) The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 28: 247-263
11. Boomsma CM et al. (2006) A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12: 673-683
12. Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24: 302-312
13. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774-800
14. Corbould A et al. (2005) Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 288: E1047-E1054
15. Polson DW et al. (1988) Polycystic ovaries-a common finding in normal women. Lancet 1: 870-872
16. Legro RS et al. (2005) Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 90: 2571-2579
17. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47
18. Robinson S et al. (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 39: 351-355
19. Adams JM et al. (2004) Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 89: 4343-4350
20. Chang PL et al. (2000) Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin- releasing hormoneagonist testing. J Clin Endocrinol Metab 85: 995-1000
21. Barber TM et al. (2007) Metabolic characteristics of women with polycystic ovaries and oligoamenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 66: 513-517
22. Azziz R et al. (2006) Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91: 4237-4245
23. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106-1118
24. Kirpichnikov D et al. (2002) Metformin: an update. Ann Intern Med 137: 25-33
25. Zhou G et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174
26. Shaw RJ et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646
27. Inzucchi SE et al. (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872
28. Maggs DG et al. (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 176-185
29. Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44: 863-870
30. Romero G and Larner J (1993) Insulin mediators and the mechanism of insulin action. Adv Pharmacol 24: 21-50
31. Nestler JE et al. (1999) Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340: 1314-1320
32. Velazquez EM et al. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647-654
33. Dunaif A et al. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 3299-3306
34. Lord JM et al. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003053. doi:10.1002/14651858.CD003053
35. Diamanti-Kandarakis E et al. (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138: 269-274
36. Azziz R et al. (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86: 1626-1632
37. Brettenthaler N et al. (2004) Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89: 3835-3840
38. Paradisi G et al. (2003) Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 576-580
39. Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352: 1223-1236
40. De Leo V et al. (2003) Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24: 633-667
41. Arlt W et al. (2001) Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 276: 16767-16771
42. Schoppee PD et al. (2002) Putative activation of the peroxisome proliferator-activated receptor γ impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod 66: 190-198
43. Mansfield R et al. (2003) Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79: 956-962
44. Nestler JE et al. (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72: 83-89
45. Fleming R et al. (2002) Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 87: 569-574
46. Maciel GAR et al. (2004) Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 81: 355-360
47. Harborne LR et al. (2005) Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 90: 4593-4598
48. Ortega-Gonzalez C et al. (2005) Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1360-1365
49. Baillargeon J-P et al. (2004) Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82: 893-902
50. Sepilian V and Nagamani M (2005) Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 90: 60-65
51. van Santbrink EJ et al. (2005) Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment. Eur J Endocrinol 152: 611-617
52. Palomba S et al. (2005) A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 20: 2879-2886
53. Tang T et al. (2006) The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 21: 1416-1425
54. Palomba S et al. (2005) Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 4068-4074
55. Moll E et al. (2006) Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332: 1485
56. Legro RS et al. (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356: 551-566
57. Palomba S et al. (2007) Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab 92: 3498-3503
58. Balen AH and Rutherford AJ (2007) Management of infertility. BMJ 335: 608-611
59. Fujioka K et al. (2003) Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a oncedaily extended-release formulation. Clin Ther 25: 515-529
60. Glueck CJ et al. (2002) Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17: 2858-2864
61. Jakubowicz DJ et al. (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87: 524-529
62. Norman RJ and Clark AM (1998) Obesity and reproductive disorders: a review. Reprod Fertil Dev 10: 55-63
63. Wang JX et al. (2000) Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study. BMJ 321: 1320-1321
64. Thatcher SS and Jackson EM (2006) Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 85: 1002-1009
65. Palomba S et al. (2004) Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 89: 4801-4809
66. Norman RJ et al. (2004) Should we continue or stop insulin sensitizing drugs during pregnancy? Curr Opin Obstet Gynecol 16: 245-250
67. Vanky E et al. (2004) Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 19: 1734-1740
68. Legro RS et al. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165-169
69. Glueck CJ et al. (2004) Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 19: 1323-1330
70. Glueck CJ et al. (2004) Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 21: 829-836
71. Glueck CJ et al. (2004) Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 19: 510-521
72. Koren G et al. (2006) Metformin use during the first trimester of pregnancy. Is it safe? Can Fam Physician 52: 171-172
73. Hellmuth E et al. (2000) Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 17: 507-511
74. Rowan JA (2007) A trial in progress: gestational diabetes: treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial) [abstract]. Diabetes Care 30: S214-S219
75. Tang T et al. (2006) Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21: 80-89
76. Pasquali R et al. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85: 2767-2774
77. Gambineri A et al. (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60: 241-249
78. Gambineri A et al. (2006) Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91: 3970-3980
79. Lord J et al. (2006) The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 113: 817-824
80. Legro RS et al. (2003) Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 88: 5137-5144
81. Diamanti-Kandarakis E et al. (2005) Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 152: 749-756
82. Kilicdag EB et al. (2005) Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 20: 894-899
83. Legro RS et al. (2007) The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 196: 402e1-402e11
84. Rouzi AA and Ardawi MSM (2006) A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 85: 428-435
85. Korytkowski MT et al. (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80: 3327-3334
86. Dahlgren E et al. (1998) Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13: 2706-2711
87. Diamanti-Kandarakis E et al. (2003) A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88: 1927-1932
88. Pasquali R et al. (1999) The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 50: 517-527
89. Costello M et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005552. doi:10.1002/14651858.CD005552.pub2
90. Meyer C et al. (2007) Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30: 471-478
91. Luque-Ramirez M et al. (2007) Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92: 2453-2461
92. Lopez LM et al. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD006133. doi:10.1002/14651858. CD006133.pub2
93. Salpeter SR et al. (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 163: 2594-2602
94. Gerstein HC et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096-1105
95. Dormandy JA et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289
96. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471
97. Home PD et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357: 28-38
98. Nathan DM (2007) Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med 357: 64-66
99. Norman RJ et al. (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13: 251-257
100. Knowler WC et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
101. Moghetti P et al. (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85: 139-146
102. Hardiman P et al. (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361: 1810-1812